Search Immortality Topics:

Page 20«..10..19202122..3040..»


Category Archives: Biotechnology

Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? – Simply Wall St

Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements.

Check out our latest analysis for Apex Biotechnology

1733s trailing twelve-month earnings (from 31 December 2019) of NT$114m has jumped 20% compared to the previous year.

Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of -28%, indicating the rate at which 1733 is growing has accelerated. Whats enabled this growth? Lets take a look at if it is merely due to industry tailwinds, or if Apex Biotechnology has experienced some company-specific growth.

In terms of returns from investment, Apex Biotechnology has fallen short of achieving a 20% return on equity (ROE), recording 6.7% instead. Furthermore, its return on assets (ROA) of 4.3% is below the TW Medical Equipment industry of 6.2%, indicating Apex Biotechnologys are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Apex Biotechnologys debt level, has declined over the past 3 years from 12% to 9.3%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 21% to 29% over the past 5 years.

Apex Biotechnologys track record can be a valuable insight into its earnings performance, but it certainly doesnt tell the whole story. Recent positive growth isnt always indicative of a continued optimistic outlook. There may be factors that are impacting the industry as a whole, thus the high industry growth rate over the same time period. You should continue to research Apex Biotechnology to get a better picture of the stock by looking at:

NB: Figures in this article are calculated using data from the trailing twelve months from 31 December 2019. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

More:
Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? - Simply Wall St

Posted in Biotechnology | Comments Off on Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? – Simply Wall St

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 …

Shire

Nanoparticles in Biotechnology and Pharmaceuticals Market: Competitive Landscape

The last chapter of the Nanoparticles in Biotechnology and Pharmaceuticals market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Nanoparticles in Biotechnology and Pharmaceuticals Market: Drivers and Restraints

The report explains the drivers of the future of the Nanoparticles in Biotechnology and Pharmaceuticals market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Nanoparticles in Biotechnology and Pharmaceuticals market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Nanoparticles in Biotechnology and Pharmaceuticals market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Nanoparticles in Biotechnology and Pharmaceuticals market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market by type and consumption forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Nanoparticles in Biotechnology and Pharmaceuticals market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

Stem Cell Alopecia Treatment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Here is the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 ...

Posted in Biotechnology | Comments Off on Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 …

Biotechnology Faculty Lecturer Joins the BPPT Covid-19 Task Force – QS WOW News

The Atma Jaya Catholic University of Indonesia (AJCUI) is contributing to reducing the Covid-19 pandemic in Indonesia. Lecturer in the Faculty of Biotechnology and Senior Researcher at BPPT, Dr. Irvan Faizal, M.Eng., has joined the TFRIC19, as the Secretary of the Task Force and the Coordinator of the Non-PCR Rapid Diagnostic Test Sub-Task Force. Lecturer of Faculty of Engineering, Dr. Ir. Lukas, MAI, CISA, IPM., is also in the task force to offer his expertise in the field of Artificial Intelligence.

The Sub-Task Force, in which Dr. Irvan is the coordinator-of, will produce a Rapid Diagnostic Test for COVID 19. In collaboration with BPPT, ITB, UNPAD, UGM, and the Research and Development Department from the Ministry of Health Research, the Rapid Diagnostic Test design for antibody detection (IgG / IgM).

I partook in the team for the reason that the competencies and abilities, especially in research and innovation, I possess, might be utilized to play a role in the handling and detecting the COVID-19 in Indonesia, said Dr. Irvan.

The lecturer in the Faculty of Biotechnology also explained that in the produced of the antibodies detection, it was designed using the COVID-19 virus from Indonesian virus isolates, hence it would be more sensitive and specific for Indonesias characteristics.

Furthermore, this sub-task force will also produce detection products using a microchip that can detect antigens so that they can be used to identify virus infections after two days of infected a person.

This innovative product may be utilized to detect COVID-19 in a patient under close monitoring (PDP) and patient under observation (ODP) in the short of time (10-15 minutes). This product expected to be more sensitive and specific for Indonesians patience in comparison to imported IgG / IgM detection, which generates low-value sensitivity and specificity, explained Dr. Irvan.

As is known, BPPT has five quick mitigation plans for the COVID-19 outbreaks. These include Whole Genome COVID-19 Origin Indonesia(analysis and forming using data from infected Indonesians),Non-PCR Diagnostic Test COVID-19 (development in the form of dip-sticks and micro-chips), andPCR Diagnostic Test COVID-19 (development following the latest mutations of COVID-19).

The other plans areCOVID-19 Pandemic Facilities and Infrastructure(strengthening suggestions and detection targets, mobile labs, health logistics, and innovation ecosystems), andArtificial Intelligence COVID-19(information technology and AI application to support diagnose and decision making).

Dr. Irvan hopes to keep supporting all teams that have performed sustained and zealously against COVID-19 in creating products that are useful in preventing, detecting, and responding to COVID-19. He advised that the community always maintain health and continue to pray.

Please support every stakeholder who had a significant concern in developing an innovative product and in research to prevent, detect, and respond to the pandemic. Take care of your health, physical distance, and keep praying, he said.

Continue reading here:
Biotechnology Faculty Lecturer Joins the BPPT Covid-19 Task Force - QS WOW News

Posted in Biotechnology | Comments Off on Biotechnology Faculty Lecturer Joins the BPPT Covid-19 Task Force – QS WOW News

Providence-based EpiVax collaborates on ongoing research for a COVID-19 vaccine – The Brown Daily Herald

As COVID-19 continues to spread throughout the country and the world, EpiVax, a biotechnology company based in Providence, is currently leading collaborative efforts to design a vaccine against the virus.

EpiVax has been dedicated to applying (their) tools to re-engineering therapeutic proteins and to designing new vaccines, according to their website. They are partnering with researchers from four organizations to work on the COVID-19 vaccine: Generex Biotechnology, the University of Georgia, Immunomic Therapeutics and an organization based in Belgium. Other researchers have reached out to the company to aid in collaborative efforts as well.

Bringing Potential Benefits

The candidate vaccines being developed by EpiVax are T-cell-based. Unlike other COVID-19 vaccines in the works that are B-cell-based, the T-cell vaccines do not stimulate antibodies, which are molecules created by the immune system to protect against infection. Some studies have proposed that in the case of COVID-19, antibody stimulation may exacerbate respiratory symptoms, said Katie Porter, EpiVaxs business development manager.

From studies on other coronaviruses, we have learned that often the antibodies are not long-lived, so they do not hold up their defense against invading viruses for extended periods of time as the virus evolves, said Lalit Beura, assistant professor of molecular microbiology and immunology, whose research involves T-cells. Having another arm of the immune system in the form of a T-cell-focused vaccine is helpful.

EpiVax: Starting with Sequencing

There are people who are concerned that were working with the actual virus in Providence, but that is not the case, Porter said. Rather, EpiVax is using a digital representation. After determining the viruss genome, the researchers selected the amino acid sequences that form the COVID-19 SARS-CoV-2 proteins that T-cells recognize and used a computer-based technology they developed to determine the regions of these proteins that instigate the greatest immune system response. The researchers will use these short protein segments to design vaccine candidates.

EpiVax has created three designs for the collaborators to use for their distinct, biological methods of delivering the vaccine. These designs include a set of distinct, short peptides, a string of connected peptides and a modified protein. Peptides are composed of the same molecules as proteins but are shorter. We are working with various collaborators on a daily basis to provide them with the best design options for their platform technology, Porter said. For instance, the Generex collaborators are using a set of peptides while the University of Georgia collaborators will be using the modified protein model consisting of the full viral protein.

While each of these organizations is working on their own projects, they all share a common goal of developing a vaccine. EpiVax has begun delivering its protein designs to its collaborators and optimizing the strains for their mechanism. For the company, sharing their sequencing and initial design work with collaborators who can help create an eventual vaccine is important because we have the ink, and we need to give it to someone with the pen so that together we can write, Porter said.

University of Georgia: Modifying the Protein Model

Ted Ross, director of the Center for Vaccines and Immunology, Georgia Research Alliance Eminent Scholar and professor of infectious diseases at the University of Georgia, and two other investigators at the university will engineer the modified protein sequences that EpiVax is designing. Then they will run trials in animal models mice and ferrets by infecting them with the altered peptides to determine whether they produce a better immune response than the wild type viruss proteins do. If this is the case, the researchers plan to expose these animals to SARS-CoV-2 to ensure that this potential vaccination is effective. The groups expectation is to have this data ready by the middle of this summer.

Ross and his group have also been working on developing a universal flu vaccine, a vaccine that could potentially be used for all influenza viruses without requiring constant changes. Perhaps we could use those (same) techniques to eventually create a universal coronavirus vaccine, Ross said.

Generex Biotechnology: Modifying the Peptide Model

Generex Biotechnology, another therapeutics company, is modifying the peptides provided by EpiVax. They are first synthesizing the peptides predicted by EpiVaxs analysis using their Ii-Key technology. An li-Key facilitates the attachment of a four-amino-acid-long peptide to a part of the COVID-19 virus. This technology serves as a sort of flag on the virus, providing a way to artificially activate the T-cells more quickly than would happen in a typical immune response.

The researchers plan on conducting their studies by testing the modified peptides, determined by EpiVax and optimized by Generex, using blood cells from COVID-19-recovered patients. They hope to complete these studies in three to four months prior to testing the potential vaccine in live animals and people.

It is a two-fold process, said Eric von Hofe, chief scientific officer of NuGenerex Immuno-Oncology, a subsidiary of Generex. The team will be looking for a T-cell response to these peptides, as well as the generation of antibodies. After starting and completing trials in animal models, Generex hopes to begin clinical trials with about 200 volunteers that will receive the peptide-based vaccine to determine whether this produces the desired immune response and to ensure the safety of the vaccine.

The biggest advantage is that peptides represent the minimal unit required to produce an immune response while reducing safety concerns associated with other proposed COVID-19 vaccines that are RNA- and DNA-based and have the potential to insert into a persons DNA, von Hofe said. But none of these types of vaccines have been approved yet for the treatment of infectious diseases, he added.

Fundamentals of Funding

Despite the preliminary successes the companies have seen thus far, funding remains a critical part of the picture. Funding often pushes back the timeline, or worse, cancels hopes of a trial continuing. EpiVaxs and Generexs earlier research on vaccine candidates for the H1N1 and SARS pandemics were halted largely due to funding limitations.

Still, the companies believe that this time around, it will not be as much of a barrier. If our trials are successful, Im sure that there will be opportunities to take a vaccine candidate even further, Porter said. There is government and other funding available, but there are many people trying to get it. We have many collaborations in place to move a COVID vaccine forward, so chances for success are very good.

Von Hofe highlighted the importance of reaching out to government officials, as well as voting for political candidates who will support vaccine research. Public interest is acute in the midst of a pandemic and then fades away, von Hofe said. But with the last 20 years having brought a handful of pandemics, now it is pretty clear that the regular emergence of pandemic or potentially pandemic viruses will not be going away, he added. Whatever happens with COVID-19, we will have learned a lot that will be applicable to whatever potential pandemic may come next; it is clear that we need to be better prepared.

While the timeline for this COVID-19 vaccines development remains indefinite, according to EpiVaxs website, were in the race to have the vaccines in clinical trials by the fall, Porter said.

See the original post:
Providence-based EpiVax collaborates on ongoing research for a COVID-19 vaccine - The Brown Daily Herald

Posted in Biotechnology | Comments Off on Providence-based EpiVax collaborates on ongoing research for a COVID-19 vaccine – The Brown Daily Herald

Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis – The Dwinnex

Puma Biotechnology Inc. [NASDAQ: PBYI] shares went higher by 12.21% from its previous closing of 8.60, now trading at the price of $9.65, also adding 1.05 points. Is PBYI stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.09 million contracts. Compared to the average trading volume of PBYI shares, the company saw a far better performance. Moreover, the stock has a 34.74M float and a 20.78% run over in the last seven days. PBYI share price has been hovering between 35.27 and 5.50 lately, and is definitely worthy of attention.

Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Puma Biotechnology Inc. [PBYI], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of 12/30/2019. On average, stock market experts give PBYI an Hold rating. The average 12-month price forecast for this stock is $9.65, with the high estimate being $15.00, the low estimate being $6.00 and the median estimate amounting to $13.50. This is compared to its latest closing price of $8.60.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Puma Biotechnology Inc. [PBYI] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on 05/06/2020.

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology Inc. [PBYI] sitting at -23.30% and its Gross Margin at 86.50%, this companys Net Margin is now -27.80. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -24.14, and its Return on Invested Capital has reached -47.06. Its Return on Equity is -302.70%, and its Return on Assets is -29.10%. These metrics suggest that this Puma Biotechnology Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 688.48. Similarly, its Total Debt to Total Capital is 87.32, while its Total Debt to Total Assets stands at 51.18. Looking toward the future, this publicly-traded companys Long-Term Debt to Equity is 673.45, and its Long-Term Debt to Total Capital is 85.41.

What about valuation? This companys Enterprise Value to EBITDA is -9.35. The Enterprise Value to Sales for this firm is now 1.07, and its Total Debt to Enterprise Value stands at 0.35. Puma Biotechnology Inc. [PBYI] has a Price to Book Ratio of 19.64, a Price to Cash Flow Ratio of 15.16.

Puma Biotechnology Inc. [PBYI] has 38.22M shares outstanding, amounting to a total market cap of 368.82M. Its stock price has been found in the range of 5.50 to 35.27. At its current price, it has moved down by -72.64% from its 52-week high, and it has moved up 75.45% from its 52-week low.

This stocks Beta value is currently 1.21, which indicates that it is 9.49% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 56.30. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Read the original:
Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis - The Dwinnex

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis – The Dwinnex

Are Robust Financials Driving The Recent Rally In Avecho Biotechnology Limited’s (ASX:AVE) Stock? – Yahoo Finance

Avecho Biotechnology's's (ASX:AVE) stock is up by a considerable 200% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Particularly, we will be paying attention to Avecho Biotechnology's ROE today.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders' Equity

So, based on the above formula, the ROE for Avecho Biotechnology is:

18% = AU$850k AU$4.8m (Based on the trailing twelve months to December 2019).

The 'return' is the income the business earned over the last year. So, this means that for every A$1 of its shareholder's investments, the company generates a profit of A$0.18.

So far, we've learnt that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

To begin with, Avecho Biotechnology seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 11%. This certainly adds some context to Avecho Biotechnology's exceptional 32% net income growth seen over the past five years. However, there could also be other causes behind this growth. Such as - high earnings retention or an efficient management in place.

Next, on comparing Avecho Biotechnology's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 32% in the same period.

ASX:AVE Past Earnings Growth April 17th 2020

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Avecho Biotechnology is trading on a high P/E or a low P/E, relative to its industry.

Avecho Biotechnology doesn't pay any dividend to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above.

In total, we are pretty happy with Avecho Biotechnology's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings.

Story continues

If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company.

You can see the 3 risks we have identified for Avecho Biotechnology by visiting our risks dashboard for free on our platform here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more here:
Are Robust Financials Driving The Recent Rally In Avecho Biotechnology Limited's (ASX:AVE) Stock? - Yahoo Finance

Posted in Biotechnology | Comments Off on Are Robust Financials Driving The Recent Rally In Avecho Biotechnology Limited’s (ASX:AVE) Stock? – Yahoo Finance